**Scientific Posters**

### ARV-based Prevention

<table>
<thead>
<tr>
<th>P001</th>
<th>Progress in HIV cascade in Russia from 2011 to 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pokrovskaya, A*; Popova, A; Suvorova, Z; Dementieva, I; Pokrovsky, V (Moscow, Russian Federation)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P002</th>
<th>Side effects of antiretroviral therapy and their association with adherence among postpartum Malawian women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whittaker, M*; Woold, S; van Lettow, M; van Oosterhout, J; Tippett Barr, B; Kim, E; Schouten, E; Auld, A; Kalua, T; Jahn, A; Landes, M (London, UK)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P003</th>
<th>Maintaining medical care for PrEP users via home sampling during the COVID-19 shutdown in Switzerland: Checkpoint@home</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hampel, B*; Drescher, S; Baumann, B; Borso, D; Hijatzi, L; Fehr, J (Zurich, Switzerland)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P004</th>
<th>Disclosure of PrEP status and its association with online sexual networking among men who have sex with men in Hong Kong</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lau, Y; Wong, N; Lee, S* (Hong Kong, Hong Kong)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P005</th>
<th>Cork University Hospital clinical audit: the management of pregnancies in HIV-positive women and the safety and efficacy of ART during pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meek, J*; Rizzo, G; Murphy, E (Cork, Ireland)</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment Strategies: New Treatments and Targets

<table>
<thead>
<tr>
<th>O414</th>
<th>Safety and efficacy of cabotegravir + rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results</th>
</tr>
</thead>
<tbody>
<tr>
<td>D’Amico, R; Orkin, C*; Bernal Morell, E; Tan, D; Katner, H; Singh, Y; Stellbrink, H; Belonosova, E; DeMoor, R; Griffith, S; Thiagarajah, S; Van Solingen-Ristea, R; Crewels, H; Ford, S; Patel, P; Cutrell, A; Smith, K; Vandermeulen, K; Margolis, D; St. Clair, M; Spreen, W (London, UK)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O416</th>
<th>Single doses of MK-8507, a novel HIV-1 NNRTI, reduced HIV viral load for at least a week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ankrom, W*; Schuermann, D; Jackson Rudd, D; Schaeffer, A; De Lepeleire, I; Friedman, E; Robberechts, M; Zhang, S; Keicher, C; Hofmann, J; Stoch, A; Iwamoto, M (West Point, PA, USA)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O442</th>
<th>A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margolis, D*; Schapiro, J; Perno, C; Kuritzkes, D; Quercia, R; Patel, P; Polli, J; Cutrell, A; Dorey, D; Wang, Y; Wu, S; van Eygen, V; Crewels, H; Ford, S; Baker, M; Talarico, C; St. Clair, M; Jeffrey, J; White, C; Vanveggel, S; Van Solingen-Ristea, R; Vandermeulen, K; Spreen, W; van Lunzen, J (Research Triangle Park, NC, USA)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P006</th>
<th>Cabotegravir + rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swindells, S*; Lutz, T; Van Zyl, L; Porteiro, N; Bennett, P; Huang, J; Harrington, C; Hove, K; Ford, S; Talarico, C; Chounta, V; Crewels, H; Van Solingen-Ristea, R; Vanveggel, S; Margolis, D; Smith, K; Vandermeulen, K; Spreen, W (Omaha, NE, USA)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P007</th>
<th>Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida*) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI + two NRTIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yakubova, E; Kravchenko, A; Shimonova, T; Bessarab, T; Sizova, N; Stepanova, E; Pokrovskaya, A; Kuimova, U; Kuznetsova, A; Radzikhovskaya, M; Pozdnyakova, L; Ulyanova, Y; Gusev, D; Yakovlev, A; Kovelenov, A; Inozemtseva, E; Baranovsky, S; Arsenko, R; Remeeva, J; Corritori, S; Savchuk, N; Dukes, I; Weichert, A; Richman, D; Murphy, R* (Chicago, IL, USA)</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Posters

**Treatment Strategies: New Treatments and Targets (continued)**

**P008** Social, psychological, and treatment-related challenges of a new HIV diagnosis in old age  
*Spinelli, F*; *Okoli, C*; *de los Rios, P*; *Nwokolo, N*; *Short, D* (Research Triangle Park, NC, USA)

**P009** HIV cure trials acceptability, representations and ethical issues among patients living with HIV: a qualitative study  
*Lesage, S*; *Gilles, I*; *Storari, C*; *Peytremann Brideaux, I*; *Barbieux, C*; *Vittoz, L*; *Calmy, A* (Lausanne, Switzerland)

**P010** Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2  
*Spinelli, F*; *Prakash, M*; *Slater, J*; *van der Kolk, M*; *Bassani, N*; *Grove, R*; *Wynne, B*; *van Wyk, J*; *Clark, A* (Research Triangle Park, NC, USA)

**P011** Comparability of 48-week efficacy and safety of cabotegravir + rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients  
*Chounta, V*; *Snedecor, S*; *Wu, S*; *Van de Velde, N* (Brentford, UK)

**P012** Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)  
*Chounta, V*; *Wu, S*; *Upadhyay, O*; *Griffith, S*; *Harrington, C*; *Orkin, C*; *Swindells, S*; *Spreen, W*; *Margolis, D* (Brentford, UK)

**P013** Experience from a real-life cohort: outcome of 984 HIV infected patients treated with bictegravir/emtricitabine/tenofovir alafenamide in Hospital Clinic, Barcelona  
*Rojas Liévano, J*; *Berrocal, L*; *Inciarte, A*; *De la Mora, L*; *González-Cordón, A*; *Martínez-Rebollar, M*; *Laguno, M*; *Torres, B*; *Ugarte, A*; *Chivite, I*; *Leal, L*; *Ambrosioni, J*; *Blanco, J*; *Martinez Chamorro, E*; *Mallolas, J* (Barcelona, Spain)

**P014** Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and physicians in western Europe  
*Akinwunmi, B*; *Buchenberger, D*; *Scherzer, J*; *Bode, M*; *Rizzini, P*; *Vecchio, F*; *Roustand, L*; *Nachbaur, G*; *Finkielsztej, L*; *Chounta, V*; *van de Velde, N* (Brentford, UK)

**P015** Long-acting treatments: people's expectations and attending physicians' preparedness. Are we ready to manage it?  
*Celesia, M*; *Cecarelli, M*; *Trezzi, M*; *Tzannis, A*; *Errico, M*; *Cinque, P*; *Focà, E*; *Ripamonti, D*; *Martini, S*; *Nozza, S*; *Gervasoni, C*; *Dentonc, C*; *Cenderello, G*; *Calcagno, A*; *Orofino, G*; *Cattelan, A*; *Tacconelli, E*; *Vichi, F*; *Saracino, A*; *Lo Caputo, S*; *De Socio, G*; *Guadagnino, G*; *Parrutti, G*; *Cingolani, A*; *Bordari, M*; *Mussini, C*; *D'ettorre, G*; *Maggi, P*; *Quirino, T*; *Madeddu, G*; *Capetti, A*; *Di Biagio, A*; *Cacopardo, B*; *Celesia, B* (Milano, Italy)

**P016** What about me? The unmet needs of men who have sex with women and differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 countries  
*Okoli, C*; *Van de Velde, N*; *Brough, G*; *Hardy, W*; *Corbelli, G*; *Allan, B*; *Muchenje, M*; *Castellanos, E*; *Young, B*; *Eremin, A*; *Ramothewala, P*; *de los Rios, P* (Brentford, UK)
P017 Outcomes for women receiving long-acting cabotegravir + rilpivirine monthly and every 2 months: ATLAS-2M study Week 48 results
Benn, P*; Quercia, R; Hudson, K; Wang, Y; Chounta, V; Talarico, C; Ford, S; Cutrell, A; Margolis, D; Van Solingen-Ristea, R; Vanveggel, S; Van Eygen, V; Polli, J; de Ruiter, A; Smith, K; Spreen, W (Brentford, UK)

P018 Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection: 3-year results from the GEMINI studies
Cahn, P*; Sierra-Madero, J; Arribas, J; Antinori, A; Ortiz, R; Clarke, A; Hung, C; Rockstroh, J; Girard, P; Sievers, J; Man, C; Urbaityte, R; Underwood, M; Pappa, K; Smith, K; Gartland, M; Aboud, M; van Wyk, J; Wynne, B (Buenos Aires, Argentina)

P019 Clinical significance of gp120 polymorphisms, temsavir IC50FC, and HIV-1 subtype in BRIGHTE
Gartland, M*; Ackerman, P; Mannino, F; Garside, L; Clark, A; Pierce, A; Krystal, M; Llamoso, C; Lataillade, M (Research Triangle Park, NC, USA)

P020 Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH: the STAT study
Rolle, C*; Berhe, M; Singh, T; Ortiz, R; Wurapa, A; Ramgopal, M; Leone, P; Matthews, J; Dalessandro, M; Underwood, M; Angelis, K; Wynne, B; Merrill, D; Nguyen, C; van Wyk, J (Orlando, FL, USA)

P021 Fostemsavir exposure-response relationships in treatment-experienced HIV patients
Parasrampuria, R*; Goyal, N; Moore, K; Ackerman, P; Llamoso, C; Barker, J; Magee, M (Collegeville, PA, USA)

P022 Model-based approach of dose selection and optimal pharmacokinetics sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection
Thakkar, N*; Magee, M; Moore, K; Ackerman, P; Chabria, S; Llamoso, C; Goyal, N (Upper Providence, PA, USA)

P023 Virological, immunological response and safety of initial antiretroviral treatment in HIV late presenters in HIV Spanish National Cohort
Bisbal, O*; Rava, M; Dominguez-Dominguez, L; Jarrín, I; Iribarren, J; Gutierrez, F; Garcia Rosado, D; Górgolas, M; Peraire, J; Poveda, E; Rubio, R; Moreno, S (Madrid, Spain)

P024 HIV-DNA decrease during treatment in primary HIV-1 infection: a randomised clinical trial with three different drug regimens
Nozza, S*; Gabrielli, A; Bernasconi, D; Marchetti, G; Calcagno, A; Ripamonti, D; Antinori, A; Squillace, N; Cauda, R; Parisi, M; Muscatello, A; Bandera, A; Tambussi, G; Rusconi, S (Milan, Italy)

P025 Clinical profile, antiretroviral drug exposure and virological status of perinatally HIV-infected adolescents transferred from paediatric to adult HIV care: 20 years of experience in a public hospital in Buenos Aires, Argentina
Cordova, E*; Arazi Caillaud, S; Rodriguez, C (Buenos Aires, Argentina)

P027 Efficacy and durability of raltegravir-based dual therapy
Cassol, C*; Dolci, G; Emiliozzi, A; Gennari, W; Bruzzone, B; Vicenti, I; Micheli, V; Borghi, V; Callegaro, A; Monno, I; Rusconi, S; Laghi, P; Lombardi, F; Zazzi, M; Fabbiani, M (Siena, Italy)
Scientific Posters

**Treatment Strategies: Target Populations (continued)**

**P028** Effect of online education on physician knowledge and confidence for the immunological drivers of depletion and recovery for CD4 T cells and implications of non-response in HIV-positive individuals  
*Duffey, J*; *Voorn, S*; *Sutton, R* (Matlock, UK)

**Treatment Strategies: Adherence**

**P029** Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice  
*Sax, P*; *Althoff, K*; *Eron, J*; *Radtchenko, J*; *Diaz-Cuervo, H*; *Mounzer, K*; *Ramgopal, M*; *Santiago, S*; *Elion, R* (Boston, MA, USA)

**P030** Cost-utility analysis of long-acting cabotegravir + rilpivirine for the treatment of HIV infection in the United Kingdom  
*Parker, B*; *Chounta, V*; *Gait, C*; *Hayward, O*; *Hunjan, M*; *Schroeder, M*; *Jacob, I*; *Van de Velde, N* (London, UK)

**P031** Beyond viral load: exploring mediating factors for the gap in optimal self-rated health by adherence status among older adults living with HIV  
*Spinelli, F*; *Okoli, C*; *de los Rios, P*; *Nwokolo, N*; *Short, D* (Research Triangle Park, NC, USA)

**P032** Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US  
*Sutton, S*; *Wang, X*; *Diaz-Cuervo, H*; *Magagnoli, J* (Columbia, SC, USA)

**P033** Self-care and involvement in managed care among people living with HIV in Europe  
*Okoli, C*; *Corbelli, G*; *Brough, G*; *Van de Velde, N*; *de los Rios, P* (Brentford, UK)

**P034** Role of patient's pathway on HIV service organisation and adherence to treatment  
*Lopatina, Y*; *Momotyuk, G*; *Zakowicz, A* (Kyiv, Ukraine)

**P035** The relationship between the quality of care perceived by the patient and adherence to antiretroviral treatment  
*Gimeno-García, A*; *Montero-Hernández, C*; *Franco-Moreno, A*; *Arponen, S*; *García-Carrasco, É*; *Alejos, B*; *Corps-Fernández, D*; *Varillas-Delgado, D*; *Gahindra-Jara, P*; *García-Navarro, M* (Torrejón de Ardoz, Spain)

**Treatment Strategies: Simplification and Switch Studies**

**O441** Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)  
*van Wyk, J*; *Ajana, F*; *Bishop, F*; *De Wit, S*; *Osiyemi, O*; *Portilla, J*; *Routy, J*; *Wyen, C*; *Ait-Khaled, M*; *Nascimento, M*; *Pappa, K*; *Wang, R*; *Wright, J*; *Wynne, B*; *Aboud, M*; *Smith, K* (Brussels, Belgium)

**P036** Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor-based regimen  
*Rockstroh, J*; *Molina, J*; *Post, F*; *Fox, J*; *Koenig, E*; *Daar, E*; *DeJesus, E*; *Ruane, P*; *Crofoot, G*; *Oguchi, G*; *Creticos, C*; *Liu, A*; *Andreatta, K*; *Graham, H*; *Brainard, D*; *Martin, H* (Bonn, Germany)
P037  Long-term treatment efficacy and safety following switch to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF): Week 144 results of the DRIVE-SHIFT trial  
Kumar, P*; Johnson, M; Molina, J; Rizzardini, G; Cahn, P; Bickel, M; Wan, H; Morais, C; Sklar, P; Greaves, W  
(Washington, DC, USA)

P038  Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older:  
Week 72 results from an international, phase IIIb, open-label trial  
Maggiolo, F*; Rizzardi, G; Molina, J; Pulido, F; De Wit, S; Vandekerckhove, L; Berenguer, J; D'Antoni, M;  
Blair, C; Chuck, S; Piontkowsky, D; Martin, H; Haubrich, R; McNicholl, I; Gallant, J (Bergamo, Italy)

P039  12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort  
Noe, S*; Ummard-Berger, K; Hillenbrand, H; Beer, D; Wyen, C; Pauli, R; Postel, N; Dymek, K; Westermayer,  
B; Scherzer, J (Munich, Germany)

P040  Early discontinuation of ABC/3TC/DTG and BIC/TAF/FTC single-tablet regimens: a real-life multicentre cohort study  
Lagi, F*; Botta, A; Arturo, C; Chiara, P; Fabbiani, M; Di Giambenedetto, S; Borghi, V; Mussini, C; Bartoloni,  
A; Gaetana, S (Firenze, Italy)

P041  Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a  
Scottish HIV cohort  
Proud, E*; Murphy, C (Glasgow, UK)

P042  Does tuberculosis coinfection increase the risk of being on second-line antiretroviral therapy in Tanzania?  
Mollel, E*; Masanja, R; Todd, J; Msuya, S; Mahande, M (Kilimanjaro, Tanzania)

P043  Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in an observational Italian cohort: interim analysis of DIAMANTE (TMC114FD1HTX4011) study  
Antinori, A; Vergori, A; Rizzardini, G; Ripamonti, D*; Esposito, V; Rusconi, S; Manzillo, E; Orofino, G;  
Andreoni, M; Lazzarin, A; Madeddu, G; Cascio, A; Uglietti, A; Termi, R; Portaro, M; Mancusi, D (Cologno Monzese, Italy)

P044  Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) +  
lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany  
Postel, N*; Schneeweiss, S; Wyen, C; Schabaz, F; Degen, O; Weinberg, G; Sabranski, M; Ummard-Berger, K;  
Dymek, K; Westermayer, B; Scherzer, J (Munich, Germany)

P045  Dual HIV treatment in experienced HIV patients  
Battagin, G*; Parisi, S; Giordani, M; Paolo, F; Mascarello, M; Del Punta, V; Luise, D; Timillero, L; Manfrin, V  
(Vicenza, Italy)
Weight gain plateaus at 24-months follow-up for ART-experienced patients that switched to dolutegavir in a Nigerian early adopter cohort

Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the BICSTaR study

O415 Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks

O416 Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (PO11) of islatravir and doravirine in treatment-naïve adults with HIV-1

Renal safety through 96 weeks from a phase II trial (PO11) of islatravir and doravirine in treatment-naïve adults with HIV-1

The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: results from the EuroSIDA study

Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+ patients over 24 months - Results from the German TAFNES cohort study

Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain

Systematic review of patient-reported outcome measures (PROMs) used in clinical trials of HIV-infected adults on combination antiretroviral therapy (cART)

Patient-reported outcomes after one year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide in PLWH: the BICSTaR cohort
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P054</td>
<td>Narrative medicine as PROs to understand living with HIV from patients' experiences: TMC114FD1HTX4011 - DIAMANTE study</td>
<td>Antinori, A; Vergori, A*; Esposito, V; Carleo, M; Andreoni, M; Malagnino, V; Rusconi, S; Castelli, F; Focà, E; Manzillo, E; Pizzella, T; Cappuccio, A; Reale, L; Fiorencis, A; Marini, M; Portaro, M; Mancusi, D; Termini, R; Uglietti, A (Rome, Italy)</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>P055</td>
<td>Perceptions of HIV-infected men who have sex with men as regards functional cure of HIV infection</td>
<td>Kwan, T*; Chan, C; Wong, N; Lee, S (Shatin, Hong Kong)</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>P056</td>
<td>Durability of F/TAF in a large cohort of PLWH seen for care in Italy</td>
<td>Vergori, A*; Cozzi Lepri, A; Gianotti, N; Calcagno, A; Guaraldi, G; Orofino, G; Moioli, M; Gentile, I; Loredana, S; Cicalini, S; d'Arminio Monforte, A; Antinori, A (Rome, Italy)</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>P057</td>
<td>Improving methods for patient-reported outcome (PRO) analyses in observational HIV studies</td>
<td>Williams, L*; Marongiu, A; Reilly, G; Heinzkill, M; Haubrich, R; Castles, R; Filippidis, F; Ramroth, H (London, UK)</td>
<td>London, UK</td>
</tr>
<tr>
<td>P058</td>
<td>Factors associated with quality of sexual life among women with HIV and HCV</td>
<td>Rodriguez, S*; Huntingdon, B; Juraskova, I; Preau, M; Etemadi, F; Galano, E; Carrieri, P; Bessonneau, P; Chassony, O; Duracinsky, M; Fofana Dara, A (Paris, France)</td>
<td>Paris, France</td>
</tr>
<tr>
<td>P059</td>
<td>Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes</td>
<td>Savchenko, M*; Panteleev, A (Saint-Petersburg, Russian Federation)</td>
<td>Saint-Petersburg, Russia</td>
</tr>
<tr>
<td>P060</td>
<td>Progressive multifocal leukoencephalopathy, still a challenge in the combined antiretroviral therapy era</td>
<td>Ianache, I; Olaru, A; Radoi, R; Nica, M; Tardei, G; Ene, L; Oprea, C* (Bucharest, Romania)</td>
<td>Bucharest, Romania</td>
</tr>
<tr>
<td>P061</td>
<td>Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults</td>
<td>Tarancón-Díez, L*; Carrasco, I; Vázquez-Alejo, E; Jiménez de Or, S; Sainz, T; Apilanez, M; Rojo, P; Guillén, S; Ramos, J; Muñoz-Fernández, M; Navarro, M (Madrid, Spain)</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>P062</td>
<td>Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes</td>
<td>Sabin, C*; Okhai, H; Dhairyawan, R; Haag, K; Burns, F; Gilson, R; Sherr, L; Tariq, S (London, UK)</td>
<td>London, UK</td>
</tr>
<tr>
<td>P063</td>
<td>Impact of baseline comorbidities on ART persistence and effectiveness in PLWH receiving F/TAF-based regimens: final 24-month results from the German TAFNES cohort study</td>
<td>Scholten, S*; Hillenbrand, H; Postel, N; Knechten, H; Pauli, R; Jessen, H; Emmerich, C; Pehlivän, C; Albuquerque, B; Haubrich, R; Stellbrink, H (Köln, Germany)</td>
<td>Köln, Germany</td>
</tr>
<tr>
<td>P064</td>
<td>Frailty of Greek PLWHIV in association with clinical markers and psychological factors: preliminary results of a nationwide study</td>
<td>Tsakona, D*; Xochelli, A; Chini, M; Meliou, M; Psychogiou, M; Basoulis, D; Panagopoulos, P; Petrakis, V; Karamanidou, C (Thessaloniki, Greece)</td>
<td>Thessaloniki, Greece</td>
</tr>
</tbody>
</table>
HIVGLASGOW
Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Cardiovascular

P065 The association of incidental coronary calcification and imaging covariates in people living with HIV. Results from the Liverpool Multiparametric Imaging Collaboration
Heseltine, T*; Murray, S; Brinksman, P; Fisher, M; McCarthy, G; Chaponda, M; Khoo, S (Liverpool, UK)

P066 Examining associations between HIV status and high blood pressure (hypertension) in a high HIV prevalence population in Manicaland, east Zimbabwe: a cross-sectional study of adults
Davis, K*; Moorhouse, L; Maswera, R; Nyamukapa, C; Smit, M; Gregson, S (London, UK)

P067 Comparing the prevalence of hypertension by HIV status in sub-Saharan African adults: a systematic review and meta-analyses of cross-sectional studies
Davis, K*; Perez Guzman, P; Gregson, S; Smit, M (London, UK)

P068 The prevalence and risk factors for peripheral artery disease in chronic kidney disease in HIV-infected persons
Viskovic, K; Marinelli, A; Nedeljko, K; Javoric, I; Bogdanic, N*; Zekan, S; Begovac, J (Zagreb, Croatia)

P069 Influence of CD4+/CD8+ ratio on early age of stroke in persons living with HIV: a single university centre study in Portugal
Pais-de-Lacerda, A*; Moreira, S; Simões Coelho, P (Lisboa, Portugal)

P070 Left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients: prevalence and associations with clinical characteristics
Basoulis, D; Athanasiadi, E; Bonou, M; Masoura, C; Skouloudi, M; Kapelios, C; Barbetseas, J; Psychogiou, M* (Athens, Greece)

P071 Transcranial Doppler pulsatility index as a marker of endothelial dysfunction, especially useful when before persistently low CD4+/CD8+ ratios
Pais-de-Lacerda, A*; Lira, A; Soares, F; Badura, R; Valadas, E; Simões Coelho, P; Oliveira, V (Lisboa, Portugal)

Co-morbidities and Complications of Disease and/or Treatment: Malignancies

O124 The relationship between smoking, CD4, viral load and cancer risk in HIV-positive adults
Mocroft, A*; RESPOND (London, UK)

P072 A 10-year case series of HHV8-related diseases in an ethnically diverse HIV cohort: is human herpesvirus 8 level a clue to the underlying pathology?
Oliveira, A*; Patel, N; Sanei, F; Sudhanva, M; Childs, K; Hamlyn, E (London, UK)

P073 Results of HPV testing from three anatomical locations among men with different HIV status and sexual behaviour
Popova, A*; Domonova, E; Pokrovskaya, A; Shipulina, O; Pokrovskiy, V (Moscow, Russian Federation)
**Co-morbidities and Complications of Disease and/or Treatment: Metabolic**

**O111** Fat distribution and density in people living with HIV with ≥5% weight gain  
Guaraldi, G*; Draisci, S; Milic, J; Carli, F; Besutti, G; Bassoli, C; Raimondi, A; Ciusa, G; Ligabue, G; Mussini, C; Erlandson, K; Brown, T; Lake, J (Modena, Italy)

**P074** NAFLD with significant fibrosis in people living with HIV informs the natural history of cardiovascular disease  
Milic, J*; Cervo, A; Carli, F; Ciusa, G; Menozzi, M; Dolci, G; Bacca, E; Rogati, C; Tutone, M; Mazzola, G; Mussini, C; Sebastiani, G (Modena, Italy)

**P075** Differential effects of raltegravir, dolutegravir and bictegravir on human adipocytes  
Domingo, P*; Quesada-López, T; Villarroay, J; Gutierrez, M; Mur, I; Corbacho, N; Mateo, G; Domingo, J; Villarroay, F; Giralt, M (Barcelona, Spain)

**P076** Genetic markers of NAFLD associated with NASH in HIV-infected patients  
Busca, C; Sanchez-Conde, M; Arias, P; Rico, M; Montejano, R; Martin-Carbonero, L; Bernardino, J; Pérez-Valero, I; Valencia, E; Moreno, V; Mican, R; Olveira, A; González-Garcia, I; Montes-Ramirez, M* (Madrid, Spain)

**P077** Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide  
Lowman, E*; Hardigan, P; Unger, N; Lee, N (Oakland Park, FL, USA)

**P078** Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone  
Bradshaw, D*; Abramowicz, J; Bremner, S; Gilleece, Y; Fedele, S; Kirk, S; Clarke, C; Williams, S; Jennings, L; Scanlon, D; Lambert, P; Verma, S; Orkin, C; Nelson, M; Gompels, M; Fox, A; Clarke, E; Chadwick, D; Perry, N (Brighton, UK)

**P079** The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: central nervous system penetration effectiveness (CPE) score evolution from baseline to 2-year follow-up  
Damas, J*; Nadin, I; Calmy, A; Assal, F; Hauser, C; Hasse, B; Schlosser, L; Tarr, P; Stoeckle, M; Kunze, U; Schmid, P; Hundsberger, T; Di Benedetto, C; Rossi, E; Ledergerber, B; Du Pasquier, R; Darling, K; Cavassini, M (Lausanne, Switzerland)

**Co-morbidities and Complications of Disease and/or Treatment: Neurological**

**P080** Clinical utility of β-amyloid PET imaging in people living with HIV with cognitive symptoms  
Vera, J*; Eftychiou, N; Schuerer, M; Rullmann, M; Barthel, H; Sabri, O; Gisslen, M; Zetterberg, H; Blennow, K; O'Brien, C; Banerjee, S; Dizdarevic, S (Brighton, UK)

**P081** CNS HIV viral escape syndrome presenting with persistent HIV viremia  
Schinold, M*; Kogilwamath, S; Fitzgerald, N; Pozniak, C (Saskatoon, Canada)

**P082** Utility of Pittsburgh Sleep Quality Index (PSQI) in PLWH for assessment and monitoring of sleep disturbance in a community HIV clinic  
Goorney, B*; Waddicar, A; Croston, M (Salford, UK)
Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Neurological (continued)

P083  Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
Tiraboschi, J*; Prieto, P; Saumoy, M; Silva, A; Imaz, A; Scevola, S; Fernandez-Olivares, G; Navarro-Alcaraz, A; Piatti, C; Podzamczer, D (L’Hospitalet, Barcelona, Spain)

P084  Perception of Spanish HIV physicians towards diagnosis and management of neuropsychiatric comorbidities in people with HIV
Pérez Valero, I*; Blanch Andreu, J; Martínez Chamorro, E (Madrid, Spain)

Co-morbidities and Complications of Disease and/or Treatment: Other

P085  Important factors related to the sexual quality of life among men living with HIV/AIDS
Etemadi, F*; Bessonneau, P; Huntingdon, B; Fofana Dara, A; Juraskova, I; Da Silva, M; Thomas, R; Griffi, J; Thonon, F; Chassany, O; Rodriguez, S; Duracinsky, M (Paris, France)

P086  Meeting the fourth 90: evaluating the mental health of an urban population of people living with HIV in a Greater London clinic
Mortimer, H*; Fowler-Williams, C; Dunin-Skrzynno, S; Cormack, I (London, UK)

P087  Gastrointestinal (GI) adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) through Week 96: an EMERALD post-hoc analysis
Dunn, K*; Baugh, B; Bejou, N; Luo, D; Campbell, J; Seyedkazemi, S (Titusville, NJ, USA)

P088  Prevalence of HIV-related stigma among participants of the Swiss HIV Cohort Study: a pilot study
Kampouri, E*; Damas, J; Jackson-Perry, D; Cobos Manuel, I; Scherrer, A; Cavassini, M; Darling, K (Lausanne, Switzerland)

P089  The prevalence of major comorbidities among people living with HIV in Croatia
Benkovic, I; Mocibob, L; Zekan, S; Lukas, D; Bogdanic, N; Begovac, J* (Zagreb, Croatia)

P090  Frailty prevalence in people living with HIV from three HIV clinics in Lisbon
Flor de Lima, B*; Silva, A; Pedro, D; Leitão, I; Pintado Maury, I; Caixeiro, M; Macedo, A (Amadora, Portugal)

P091  Importance of screening for depression in people living with HIV in Ukraine
Lopatina, Y; Momotyuk, G; Zakowicz, A*; Kalandia, H (Amsterdam, Netherlands)

P092  Analysis of adherence to HIV-positive quality of care indicators and their impact on health-related quality of life: a Spanish cross-sectional study
Gimeno-Garcia, A*; Montero-Hernández, C; Franco-Moreno, A; Arponen, S; Garcia-Carrasco, É; Corps-Fernández, D; Alejas, B; Varillas-Delgado, D; Galindo-Jara, P; Garcia-Navarro, M (Torrejón de Ardoz, Spain)

P093  Real-world characterisation of the Portuguese population living with HIV who initiated raltegravir-based regimen between 2015 and 2017 - REALITY study
Serrão, R; Mansinho, K; Maltez, F; Marques, N; Carvalho, A; Pazos, R; Zagalo, A; Mendez, J; Neves, I; Oliveira, J; Pacheco, P; Correia de Abreu, R; Miranda, A*; Camacho, A; Paixão, L; Almeida, J (Lisboa, Portugal)
### Viral Hepatitis

**P094** Phylodynamics of sexually acquired HCV-3a in HIV co-infected patients in Hong Kong  
*Kwan, T*; *Wong, B; Chan, D; Wong, N; Lee, S (Shatin, Hong Kong)*

**P095** Efficacy, safety and convenience of integrase strand transfer inhibitors-based ART regimens in people living with HIV coinfected with hepatitis C and/or B viruses  
*Carosi, G*; *Rich, S; Prosperi, M; Mazzini, N; Nasta, P; Quiros Roldan, E; Di Filippo, E; Cauda, R; Saracino, A; Angaranò, G; Vichi, F; Esperti, S; Sighinolfi, L; Segala, D; Lapdaula, G; Bonfanti, P; Fornabaio, C (Brescia, Italy)*

**P096** Hepatitis C infection and treatment outcomes in the direct-acting antiviral era  
*Jewsbury, S*; *Newton, P; Tomkins, A; Garner, A; Teo, S; Ahmad, S; Saxon, C; Ward, C; Prince, M; Lee, V (Manchester, UK)*

**P097** Features of HIV and HCV epidemics in central part of Ukraine  
*Koval, T*; *Marchenko, O; Sabinina, O; Koval, A (Poltava, Ukraine)*

### Clinical Pharmacology

**P098** Evaluation and clinical application of fostemsavir co-administration with tuberculosis medications  
*Moore, K*; *Nguyen, D; Tai, G; Magee, M; Gorycki, P; Lee, T; Ackerman, P; Llamoso, C; Clark, A (Research Triangle Park, NC, USA)*

**P099** Safety, tolerability, and pharmacokinetics following single- and multiple-dose administration of the novel NNRTI MK-8507 with a midazolam interaction arm  
*Ankrom, W*; *Schaeffer, A; Panebianco, D; Friedman, E; Tomek, C; Stoch, A; Iwamoto, M (Kenilworth, NJ, USA)*

**P100** The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide - Real-world data from the German IQVIA prescription database  
*Umland, T*; *Stellbrink, H; Calvo, M; Zahn, A (Hamburg, Germany)*

**P101** Development and clinical validation of an liquid chromatography with ultraviolet detection method to quantify dolutegravir in dried blood spots  
*Akinloye, A*; *Adeagbo, B; Bolaji, O; Olagunju, A (Ile-Ife, Nigeria)*

**P102** Fostemsavir and ethinyl estradiol drug interaction: clinical application for coadministration  
*Nwokolo, N*; *Post, E; Magee, M; Ackerman, P; Llamoso, C; Moore, K (Brentford, UK)*

### Community Initiatives

**P103** Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA) in Italy and correlation with the level of confidence in reference physicians  
*Cingolani, A*; *Tavelli, A; Calvino, G; Maggiolo, F; Girardi, E; Cozzi-Lepri, A; Perziano, A; Comoseragna, A; Gagliardini, R; Nozza, S; Antinori, A; d'Arminio Monforte, A (Rome, Italy)*
Community Initiatives (continued)

**P104** What’s trending in Asia? Drawing inferences from online HIV support seeking patterns of risk groups in Asia using regional Adam’s Love and TemanTeman.org big datasets
*Anand, T; Nitpolprasert, C* (Bangkok, Thailand)

**P105** HIV prevention among MSM in Japan: current opinions on achieving the first 90 among Japanese MSM
*Anand, T; Nitpolprasert, C*; Shirasaka, T; Iwatani, Y; Yokomaku, Y; Imahashi, M; Kaneko, N; Iwahashi, K; Ikushima, Y; Aoki, R; Ishida, T; Shiono, S; Yamaguchi, M; Takemura, K; Iwamoto, A (Bangkok, Thailand)

**P107** Thinking outside the box: evaluating the impact of a virtual classroom model to deliver HIV primary care education to physicians and nurse practitioners across Saskatchewan, Canada
*Stewart, K; Kogilwaimath, S*; Galambos, A (Saskatoon, Canada)

**P109** Sexual behaviours and associated factors among men living with HIV in Istanbul, Turkey
*Kumbasar Karaosmanoglu, H*; Altuntas Aydin, O; Yesilbag, Z (Istanbul, Turkey)

**P110** Capacity building for youth coalitions, critical for sustaining gains in HIV prevention sphere
*Ita, D*; Alaka, O; Durueke, F (Lagos, Nigeria)

Models of Care: Cost Effectiveness and Evaluation of Delivery and Coverage

**P111** EmERGE: feasibility and uptake of a co-designed digital health supported pathway of care for people living with medically stable HIV
*Whetham, J*; Jones, C; Bremner, S; Apers, L; Begovac, J; Borges, M; Leon, A; Vera, J; Zekan, S; West, B; Chausa, P; Gomez, E; Garcia, F; EmERGE Consortium (Brighton, UK)

**P112** Differences in patient-reported outcomes among single- and multi-tablet regimens
*Degroote, S*; Vanden Bulcke, C; Vogelaers, D; Vandekerckhove, L (Ghent, Belgium)

**P113** Community responses on variability in the frequency of patient visits to HIV clinics in the EU
*Greenhalgh, F; West, B*; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)

**P114** Modelling the future of HIV in Turkey: disease implications of improving prevention, diagnosis and treatment
*Yaylali, E*; Gökengin, D; Korten, V; Tabak, F; Ünal, S; Erdogan, Z; Çalışır, F; Özelgün, B; Şahin, T (Istanbul, Turkey)

**P115** To 90-90-90 and beyond: feasibility and clinical outcomes of same-day ART initiation among PLHIV in a real-life, middle-income setting
*Barletta, J*; Jaume, M; De Ilzarbe, M; Bruno, D; Romero, A; Tokumoto, N; Vigo, G; Díaz, L; Cando, O; Rolán, M (Buenos Aires, Argentina)

**P116** Community responses about access to and importance of telemedicine by PLHIV and clinical staff in the EU
*Greenhalgh, F; West, B*; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)

**P117** Ensuring continuity of care for people living with HIV in five European countries: the efficiency of the EmERGE platform
*Beck, E*; Mandalia, S; Yfantopoulos, P; Leon, A; Merino, M; Garcia, F; Wittevrongel, M; Apers, L; Benkovic, I; Zekan, S; Begovac, J; Cunha, A; Teofilo, E; Rodrigues, G; Borges, M; Fatz, D; Vera, J; Whetham, J (London, UK)
### Models of Care: Cost Effectiveness and Evaluation of Delivery and Coverage (continued)

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P118</td>
<td>To 90-90-90 and beyond: a community-focused multimodal, interdisciplinary intervention to optimise continuum of care among recently diagnosed PLHIV in a middle-income setting</td>
<td>De Ilzarbe, M*; Bruno, D; Jaume, M; Barletta, J; Romero, A; Tokumoto, N; Vigo, G; Diaz, L; Cando, O; Rolón, M (Buenos Aires, Argentina)</td>
</tr>
<tr>
<td>P119</td>
<td>Comprehensive retention to care model: results of the pilot in Krasnoyarsk, Russia 2016-2019</td>
<td>Kandlen, K*; Chuykov, A; Boiko, A; Burdina, Y; Zakowicz, A; Mironova, N (Saint Petersburg, Russian Federation)</td>
</tr>
</tbody>
</table>

### Virology and Immunology

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O323</td>
<td>Impact of multi-drug resistance on mortality: a multi-cohort Italian study</td>
<td>Gagliardini, R*; Cozzi-Lepri, A; Zazzi, M; Tavelli, A; Santoro, M; Armenia, D; Castagna, A; Gennari, W; Rusconi, S; Mussini, C; Laghetti, P; Perno, C; D’Arminio Monforte, A; Antinori, A (Rome, Italy)</td>
</tr>
<tr>
<td>O324</td>
<td>Lenacapavir resistance analysis in a phase Ib clinical proof-of-concept study</td>
<td>Margot, N*; Ram, R; Parvangada, P; Martin, R; Hyland, R; Rhee, M; Callebaut, C (Foster City, CA, USA)</td>
</tr>
<tr>
<td>O443</td>
<td>Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults infected with HIV: a phase III trial</td>
<td>Mohapi, L; Osiyemi, O*; Supparatpinyo, K; Ratanasuwann, W; Molina, J; Dagan, R; Tamms, G; Sterling, T; Zhang, Y; Hartzel, J; Pedley, A; Kan, Y; Hurtado, K; Buchwald, U; Musey, L; Simon, J (West Palm Beach, FL, USA)</td>
</tr>
<tr>
<td>P120</td>
<td>Islatravir selects for HIV-1 variants in MT4-GFP cells that profoundly reduce replicative capacity in peripheral blood mononuclear cells</td>
<td>Diamond, T*; Ngo, W; Xu, M; Goh, S; Rodriguez, S; Lai, M; Asante-Appiah, E; Grobler, J (Kenilworth, NJ, USA)</td>
</tr>
<tr>
<td>P121</td>
<td>Impact of resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current single-tablet regimens (STRs)</td>
<td>Rossetti, B*; Di Carlo, D; Fabbiani, M; Stella, G; Vicenti, I; Maggiolo, F; Gennari, W; Francisci, D; Santoro, M; Zazzi, M (Siena, Italy)</td>
</tr>
<tr>
<td>P122</td>
<td>Impact of genetic variation of the APOBEC3G gene on HIV RNA, T-cell counts, markers of inflammation and clinical events</td>
<td>Domínguez-Domínguez, L*; Reekie, J; Leung, P; Zucco, A; Novak, R; Gilson, R; Stephan, C; Rupasinghe, D; Helleberg, M; MacPherson, C; Lundgren, J; Murray, D; INSIGHT START Study Group (Copenhagen, Denmark)</td>
</tr>
<tr>
<td>P123</td>
<td>Sustained viral suppression after switch to bicitravir/emtricitabine/tenofovir alafenamide among clinical trial participants with preexisting M184V/I</td>
<td>Andreatta, K*; Acosta, R; D’Antoni, M; Porter, D; Chang, S; Martin, R; Willkom, M; McNicholl, I; Gallant, J; Pikora, C; Graham, H; Collins, S; Martin, H; White, K (Foster City, CA, USA)</td>
</tr>
<tr>
<td>P124</td>
<td>Bicitravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F</td>
<td>Acosta, R*; Andreatta, K; D’Antoni, M; Collins, S; Martin, H; White, K (Foster City, CA, USA)</td>
</tr>
<tr>
<td>P125</td>
<td>Development of integrase inhibitor resistance under first-line treatment with bicitravir</td>
<td>Stoll, M; Braun, P*; Wiesmann, F; Knechten, H (Aachen, Germany)</td>
</tr>
</tbody>
</table>
### Virology and Immunology (continued)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P126</td>
<td>Barriers for participation in HIV vaccine trials among general population in Argentina: first interim survey</td>
<td>Cecchini, D*; Ballivian, J; Feld, D; Cassetti, I (Buenos Aires, Argentina)</td>
</tr>
<tr>
<td>P127</td>
<td>Improving the HIV testing cascade: adequate identification of patients with HIV indicator conditions in hospitals by electronic registration systems</td>
<td>Jordans, C*; Hensley, K; Vogel, M; van Kampen, J; Boucher, C; Mollema, F; Gisolf, J; El Moussaoui, R; Hermanides, G; van der Valk, M; Finkenflügel, R; Rijnders, B; Verbon, A; Rokx, C (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>P128</td>
<td>Routine, automated and clinician independent universal screening of HIV infection in an emergency department: reducing late presentation by overcoming barriers to testing</td>
<td>Vaz Pinto, I*; Guimaraes, M; Castro, V; Santos, C; Galiano, A; Friaes, J; Bilé, A (Alcabideche, Portugal)</td>
</tr>
<tr>
<td>P129</td>
<td>Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3rd) in late and very late presenters: final 24-month results from the German TAFNES cohort study</td>
<td>Postel, N*; Jessen, H; Pauli, R; Hillenbrand, H; Heuchel, T; Rieke, A; Knechten, H; Emmerich, C; Schreiber, S; Mack, F; Haubrich, R; Stellbrink, H (Munich, Germany)</td>
</tr>
<tr>
<td>P130</td>
<td>Late presenters of HIV infection during COVID-19 pandemic</td>
<td>Panagopoulos, P; Petrakis, V*; Kyrgiannaki, V; Kriaraki, Z; Papazoglou, D (Alexandroupolis, Greece)</td>
</tr>
</tbody>
</table>

### COVID-19

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O242</td>
<td>STI and HIV testing to break the chain of infection: local innovation in the midst of COVID-19</td>
<td>Wood, C*; Ahmad, S; Jewsbury, S; Redmond, M; Saxon, C; Sukthankan, A; Thomas, D; Ward, C; McQuillan, O (Manchester, UK)</td>
</tr>
<tr>
<td>O422</td>
<td>Outcomes of COVID-19 related hospitalisation among people with HIV in the United Kingdom and comparison to those without HIV</td>
<td>Geretti, A*; Stockdale, A; Kelly, S; Villa, G; Turtle, L; Semple, M; Sabin, C (Liverpool, UK)</td>
</tr>
<tr>
<td>O444</td>
<td>SARS-CoV-2 infection in pregnancy and newborn in a Spanish multicentric cohort (GESNEO-COVID)</td>
<td>Carrasco, I*; Muñoz, M; Vigil, S; Aguilera, D; Riaza, M; Sanz, O; Pareja, M; Baña, A; Sanchez Luna, M; Navarro, M (Madrid, Spain)</td>
</tr>
<tr>
<td>P131</td>
<td>Resilience and frailty in people living with HIV during the lockdown experience in Italy in March-May 2020: are they two complementary constructs?</td>
<td>Guaraldi, G*; Milic, J; Ciusa, G; Raimondi, A; Cuomo, G; Carli, F; Mussini, C (Modena, Italy)</td>
</tr>
<tr>
<td>P132</td>
<td>Impact of COVID pandemic among men who have sex with men living with HIV during COVID lockdown in Argentina</td>
<td>Ballivian, J*; Cecchini, D; Alcaide, M; Abbamonte, J; Jones, D; Cassetti, I (Buenos Aires, Argentina)</td>
</tr>
<tr>
<td>P133</td>
<td>COVIDApp: a health application as an innovative strategy for the management of the COVID-19 pandemic in long-term care facilities</td>
<td>Echeverría, P*; Mas, M; Puig, J; Isnard, M; Massot, M; Vedia, C; Peiró, R; Ordonica, Y; Pablo, S; Ulldemolins, M; Iruela, M; Balart, D; Ruiz, J; Herms, J; Clotet, B; Negredo, E (Barcelona, Spain)</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors and Details</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P134</td>
<td>SARS-CoV2 pandemic: SARS-CoV2 seroprevalence and impact on HIV suppression in PLWH</td>
<td>Cuomo, G*; Bacca, E; Menozzi, M; Carli, F; Borghi, V; Guaraldi, G; Mussini, C (Modena, Italy)</td>
</tr>
<tr>
<td>P135</td>
<td>Prevalence of respiratory virus infections during a SARS-CoV2 epidemic</td>
<td>Sukach, M*; Ingiliz, P; Valin, N; Boussaid, K; Julienn, J; Chiarabini, T; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)</td>
</tr>
<tr>
<td>P136</td>
<td>Prophylactic dose of low-molecular-weight heparin (LMWH) might not be sufficient to mitigate the clinical scenario in patients with COVID-19 and severe pneumonia</td>
<td>Vergori, A*; Donno, D; Lorenzini, P; Nicastrì, E; Gualano, G; Iacomi, F; Marchioni, L; Schininà, V; Cicalini, S; Agrati, C; Capobianchi, M; Girardi, E; Ippolito, G; Vaia, F; Petrosillo, N; Antinori, A; Taglietti, F (Rome, Italy)</td>
</tr>
<tr>
<td>P137</td>
<td>Symptoms of viral infection and polymerase chain reaction (PCR) positivity rates of SARS-CoV2 in healthcare professionals in Paris, France</td>
<td>Sukach, M*; Ingiliz, P; Valin, N; Barbut, F; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)</td>
</tr>
<tr>
<td>P138</td>
<td>Understanding how HIV testing has been affected by the COVID-19 response</td>
<td>Greenhalgh, F; Von Lingen, A; Cigan, B*; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)</td>
</tr>
<tr>
<td>P139</td>
<td>Cross-border movement restrictions during Covid-19 and foreign nationals' access to healthcare and medicines</td>
<td>Greenhalgh, F; Von Lingen, A*; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)</td>
</tr>
<tr>
<td>P140</td>
<td>The impact of COVID-19 epidemic on HIV care in Croatia</td>
<td>Bogdanic, N*; Zekan, S; Romih Pintar, V; Lukas, D; Begovac, J (Zagreb, Croatia)</td>
</tr>
<tr>
<td>P141</td>
<td>Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago</td>
<td>Sherer, R*; Lehmann, C; Zhu, M; Lio, J (Chicago, IL, USA)</td>
</tr>
<tr>
<td>P142</td>
<td>Effect of first 3 months of COVID pandemic on HIV services in Greece: a short survey among HIV physicians</td>
<td>Lourida, G*; Leonidou, L; Psychogiou, M; Chrysanthidis, T; Protopappas, K; Katsarolis, I; Xylomenos, G; Panagopoulos, P; Chini, M; Papastamopoulos, V (Athens, Greece)</td>
</tr>
<tr>
<td>P143</td>
<td>Fears and perception of the risk of infection with SARS-CoV-2 in a cohort of HIV+ subjects on antiretroviral treatment in an outpatient clinic in Sicily</td>
<td>Ceccarelli, M*; Marino, A; Accordino, S; Lupo, G; Boscia, V; Cosentino, F; Moscatt, V; Bruno, R; Pampaloni, A; Scuderi, D; Cacopardo, B; Celesia, B (Catania, Italy)</td>
</tr>
<tr>
<td>P144</td>
<td>How has the COVID-19 response changed medicine deliveries for people living with or at risk of HIV?</td>
<td>Greenhalgh, F; Von Lingen, A; Cigan, B*; Varasi, P; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)</td>
</tr>
</tbody>
</table>
COVID-19 (continued)

P145  Characterisation of PLWH with COVID-19 in a tertiary care reference centre for emerging infectious diseases in Portugal
Nunes Silva, C*; Caldas, J; Martins, A; Policarpo, S; Rocha, R; Freitas, F; Mesquita, M; Abreu, I; Graça, L; Palma Martins, P; Ceia, F; Pineiro, C; Neves, N; Silva, S; Tavares, M; Serrão, R; Sarmento, A (Porto, Portugal)

P146  Assessing the mental health of people living with HIV in Scotland during COVID-19
Hirono, J*; Sparling, N (Edinburgh, UK)

P147  Characteristics and outcomes of inpatient COVID-19 infections in people living with HIV
Jewsbury, S*; Garner, A; Houston, J; Polden, M; Saxon, C; Tomkins, A; Lee, V (Manchester, UK)

P148  SARS-CoV-2 infection in HIV patients: we anticipated a worse scenario
Bastos, L*; Pocinho, S; Machado, A; Guerreiro, G; Domingos, J; Miranda, C; Goncalves, E; Fonseca, C; Mansinho, K (Lisboa, Portugal)

P149  Understanding how the COVID-19 response affects the quality of care services for people living with HIV and communities affected by HIV
Greenhalgh, F; Von Lingen, A*; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)